Opthalmology
National survey aims to improve glaucoma care across the UK
July 16, 2026Glaucoma UK, Opthalmology
Glaucoma UK has launched the National Patient Voices Survey, a nationwide study designed to capture the experiences of around 10,000 …
New web series explores path from ophthalmic research to patient access
April 28, 2026Research and Development Opthalmology
A new YouTube web series has been launched to examine how ophthalmic innovations progress from early research through to approved …
Regeneron announces presentations of new data on Eylea HD for retinal disease
February 18, 2026Research and Development Eylea HD, Opthalmology, Regeneron
Regeneron has presented data for Eylea HD (aflibercept) 8mg injection for retinal disease. The data was presented as part of …
Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
January 22, 2026Research and Development Complement Therapeutics, FDA, Opthalmology, geographic atrophy
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), …
EMA grants orphan drug designation for Roca’s treatment of radiation maculopathy
August 28, 2025Medical Communications, Research and Development European Medicines Agency (EMA), Oncology, Opthalmology, Roca Therapeutics, maculopathy
The European Medicines Agency (EMA) has granted Orphan Drug Designation to Roca Therapeutics for its lead candidate RCT002, marking the …
Eyestem secures $10m to advance cell therapy for advanced eye disease
August 13, 2025Medical Communications, Research and Development Eyestem, Opthalmology, cell therapy, dry age-related macular degeneration, geographic atrophy
Indian cell therapy company, Eyestem Research, has raised $10m in a funding round to support development of its investigational retinal …
NICE recommends treatment for rare genetic eye disorder
August 11, 2025Medical Communications Chiesi, Leber Hereditary Optic Neuropathy, NHS England, National Institute for Health and Care Excellence, Opthalmology, Rare Diseases
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Cheisi’s idebenone (Raxone) within its …
Horus Pharma expands distribution in North Africa and the Middle East
August 8, 2025Mergers and Acquisitions, Research and Development Corporate, Horus Pharma, Opthalmology, distribution agreement
Ophthalmology company, Horus Pharma, based in Nice, France, has extended its global presence through new distribution agreements across eight countries …
OKYO Pharma reports promising phase 2 results for urcosimod in neuropathic corneal pain
July 24, 2025Research and Development OKYO Pharma, Opthalmology, clinical trial, neuropathic corneal pain, ocular pain
OKYO Pharma has announced positive results from its phase 2 trial of urcosimod (formerly OK-101) in neuropathic corneal pain (NCP), …
Addenbrooke’s hospital offers first self-service digital eye test
July 17, 2025Research and Development Addenbrooke's Hospital, Cambridge, Opthalmology, UK, eye test, ophthalmology
Addenbrooke’s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing system – DigiVis DVA system …
Eyestem completes phase 1 trial of retinal cell therapy with promising vision gains
June 20, 2025Research and Development Eyestem Research, Opthalmology, cell therapy, clinical trial, dry age-related macular degeneration, geographic atrophy
Eyestem Research has announced the successful completion of its phase 1 trial evaluating Eyecyte-RPE, an investigational cell therapy for geographic …
Treatment for serious eye disease approved in Scotland
June 12, 2025Market Access, Marketing Services, Research and Development, Sales and Marketing LYTENAVA, Opthalmology, Scottish Medicines Consortium, clinical programme, european union, eye disease, market approval, strategic partnership, united kingdom, wet age-related macular degeneration
Outlook Therapeutics has announced the Scottish Medicines Consortium (SMC) approval of Lytenava (bevacizumab gamma) for the treatment of wet age-related …
Galimedix completes key stage of clinical trial for treatment targeting eye and brain diseases
May 9, 2025Research and Development Galimedix Therapeutics, Neurology, Opthalmology, R&D, clinical trial, neurodegenerative conditions
Clinical biotech, Galimedix Therapeutics, has announced the completion of a single ascending dose (SAD) part of a phase 1 study …
Successful trial results announced for potential rare eye disease treatment
April 14, 2025Research and Development Eyestem, Opthalmology, age-related macular degeneration (AMD), biotech, cell therapy, eye disease
Eyestem Research, an Indian biotech company, announced successful results from its phase 1 trial of Eyecyte-RPE, a potential therapy for …
Nordic Pharma’s Lacrifill canalicular gel gains CE mark approval and set for European launch
April 14, 2025Market Access, Research and Development, Sales and Marketing Nordic Pharma, Opthalmology, dry eye disease
International pharma company Nordic Pharma has announced that its Lacrifill treatment for dry eye disease has received European Conformity (CE) …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
